** Shares of drug developer Alnylam Pharmaceuticals ALNY.O rise 6.5% to $270 premarket
** On Thursday, US FDA approved ALNY's injectable drug, Amvuttra, to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and deadly heart disease
** Amvuttra was first approved in 2022 to treat nerve damage related to ATTR-CM
** Amvuttra is the first treatment to address both nerve and heart forms of ATTR-CM, working by reducing production of the disease-causing protein
** List price of Amvuttra is $119,351 per prefilled syringe, administered every 3 months, with no planned change for ATTR-CM treatment
** Brokerage Jefferies said it expects Amvuttra's price to decrease over time as prescription volumes rise, with initial impacts likely in the H2 of this year
** ALNY gained 71.4%, in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。